Arranta Bio Acquires Captozyme
November 13, 2019
Arranta Bio has acquired Captozyme and integrated its Gainesville, Florida team and facilities to create a Center of Excellence for microbiome process and analytical development and early clinical supply. The acquisition expands Arranta's CDMO capabilities for live biotherapeutics and transfers Captozyme's clinical GMP capacity while Captozyme's enzyme therapeutic assets were spun out into Oxidien Pharmaceuticals.
- Buyers
- Arranta Bio
- Targets
- Captozyme
- Platforms
- Arranta Bio
- Industry
- Biotechnology
- Location
- Florida, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Recipharm Acquires Arranta Bio
February 18, 2022
Biotechnology
Recipharm has acquired Arranta Bio, a US-based CDMO specializing in advanced therapy medicinal products (ATMPs), microbiome therapeutics and mRNA manufacturing, to expand its biologics and ATMP capabilities and establish a stronger US presence. Arranta Bio brings fermentation, purification, analytics and end-to-end mRNA drug substance and drug product capabilities; the transaction was expected to close around the end of March 2022.
-
Verdesian Life Sciences Acquires Cytozyme Laboratories
April 27, 2021
Agriculture
Verdesian Life Sciences has acquired Cytozyme Laboratories, Inc.; Cascadia Capital served as exclusive financial advisor to Cytozyme. The acquisition brings together complementary biological and nutritional crop technologies to expand Verdesian's product portfolio and support sustainable yield solutions for growers.
-
BioMarin Acquires Inozyme Pharma
May 16, 2025
Biotechnology
BioMarin Pharmaceutical Inc. completed its acquisition of Inozyme Pharma, Inc. in an all-cash transaction valued at approximately $270 million ($4.00 per share). The deal adds Inozyme's late-stage enzyme replacement therapy INZ-701 for ENPP1 Deficiency to BioMarin's enzyme-therapy portfolio and is expected to accelerate development toward potential regulatory approval.
-
Certara Acquires Chemaxon to Expand Drug Discovery Software Capabilities
July 9, 2024
Software
Certara, Inc. has signed a definitive agreement to acquire Chemaxon, a leading cheminformatics software provider, with the transaction expected to close in the second half of 2024, subject to regulatory approvals. The acquisition adds Chemaxon’s discovery-focused cheminformatics tools to Certara’s biosimulation portfolio, enabling a more comprehensive data and predictive-analytics platform spanning discovery through development.
-
Bruker Corporation Acquires ZONTAL Inc.
May 8, 2023
Software
Bruker Corporation has closed the acquisition of ZONTAL Inc., a provider of a GxP-compliant life-sciences data platform, to strengthen Bruker BioSpin's Integrated Data Solutions (IDS) software portfolio. The deal (terms not disclosed) will integrate ZONTAL's vendor-agnostic laboratory and process data management capabilities with Bruker's Mestrelab, Arxspan and Optimal offerings to accelerate digital laboratory transformation for biopharma and life-science customers; ZONTAL expected 2023 revenues of greater than $5 million.
-
CellCarta Acquires Biogazelle
December 14, 2021
Biotechnology
CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.